《自然》重磅解读“双效减脂法”！全新瘦身利器有望让“爆款减肥药”相形失色

Core Viewpoint - The article discusses the revolutionary impact of GLP-1 receptor agonists in obesity treatment, highlighting recent advancements in combining these drugs with NMDA receptor antagonists to enhance weight loss effects [6][8][14]. Summary by Sections GLP-1 Receptor Agonists - In 2021, the FDA approved semaglutide, a GLP-1 receptor agonist, for long-term weight management in obese and overweight adults, showing an average weight reduction of 15% with weekly injections [6]. - GLP-1 receptor agonists were initially approved for type 2 diabetes treatment, with their weight loss effects discovered during early clinical trials [8]. Innovative Combination Therapy - Researchers from Copenhagen University proposed a novel approach by combining GLP-1 receptor agonists with NMDA receptor-targeting drugs to achieve a dual weight loss effect [8]. - NMDA receptors play a significant role in appetite regulation, and previous studies have shown that NMDA receptor antagonists can induce anorexia and weight loss in mice [11]. Experimental Findings - In experiments with diet-induced obese mice, the new GLP-1–MK-801 compound resulted in a remarkable weight reduction of 23.2%, outperforming traditional calorie restriction methods [13]. - The compound maintained metabolic rates comparable to obese mice, addressing the common issue of metabolic compensation during weight loss [13]. Safety and Future Research - The safety evaluation of GLP-1–MK-801 indicated no severe adverse reactions in mice, supporting further development of this innovative drug [14]. - Future studies are needed to assess the long-term effects and safety of GLP-1–MK-801, with the potential to become a more powerful treatment option than existing weight loss medications [14]. Current GLP-1 Weight Loss Drugs - A list of GLP-1 weight loss drugs currently in various clinical stages includes: - Mounjaro (Tirzepatide) - FDA approved - Wegovy (Semaglutide) - FDA approved - Saxenda (Liraglutide) - FDA approved - Several others in clinical trials [15].